Futura Medical (LSE:FUM) has received formal approval for a continuation patent in the United States that extends intellectual property protection until 2040 for its erectile dysfunction treatment Eroxon, its enhanced formulation Eroxon Intense, and the company’s women’s sexual health candidate WSD4000.
The newly granted patent strengthens Futura’s intellectual property portfolio in one of its most important markets, providing longer-term protection for both its lead product and pipeline therapies focused on sexual health.
Under the company’s existing licensing agreement with Haleon, the patent grant is expected to trigger a $2.5 million milestone payment. The payment will provide near-term non-dilutive funding and further supports Futura’s financial position as it continues commercial expansion of its products. The strengthened patent coverage also enhances the company’s competitive position within the growing over-the-counter sexual health market for both men and women.
Despite these developments, Futura’s outlook remains constrained by several factors. Management recently lowered its FY2025 expectations, and the company continues to operate with a relatively short cash runway. Technical indicators also suggest a weak share price trend. These challenges are partly offset by the company’s return to profitability in FY2024 and its debt-free balance sheet. However, continued negative free cash flow keeps the company’s overall financial quality mixed.
More about Futura Medical
Futura Medical plc is a consumer healthcare company focused on developing and commercialising innovative topical gel treatments for sexual health conditions. Its flagship product, Eroxon, is an over-the-counter gel designed to treat erectile dysfunction. The company is also advancing additional products, including Eroxon Intense and WSD4000, aimed at addressing female sexual dysfunction. Together, these therapies target large global markets that remain significantly underserved.
Leave a Reply